Repligen Corporation (RGEN) Shares Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System increased its position in shares of Repligen Corporation (NASDAQ:RGEN) by 9.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,100 shares of the biotechnology company’s stock after buying an additional 1,300 shares during the period. Louisiana State Employees Retirement System’s holdings in Repligen Corporation were worth $626,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. State of Alaska Department of Revenue increased its position in Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock worth $131,000 after buying an additional 80 shares during the last quarter. NBW Capital LLC boosted its stake in Repligen Corporation by 0.5% in the first quarter. NBW Capital LLC now owns 22,655 shares of the biotechnology company’s stock worth $797,000 after buying an additional 118 shares during the period. Arizona State Retirement System boosted its stake in Repligen Corporation by 1.1% in the first quarter. Arizona State Retirement System now owns 17,626 shares of the biotechnology company’s stock worth $620,000 after buying an additional 200 shares during the period. NN Investment Partners Holdings N.V. boosted its stake in Repligen Corporation by 1.4% in the second quarter. NN Investment Partners Holdings N.V. now owns 35,445 shares of the biotechnology company’s stock worth $1,469,000 after buying an additional 495 shares during the period. Finally, Mason Street Advisors LLC boosted its stake in Repligen Corporation by 7.0% in the first quarter. Mason Street Advisors LLC now owns 7,914 shares of the biotechnology company’s stock worth $279,000 after buying an additional 521 shares during the period. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Repligen Corporation (NASDAQ:RGEN) traded up 1.7120% during trading on Tuesday, reaching $43.2581. 68,699 shares of the company’s stock traded hands. The firm’s 50 day moving average is $41.28 and its 200-day moving average is $36.10. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 114.1375 and a beta of 1.30.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The business had revenue of $32.40 million during the quarter, compared to analysts’ expectations of $31.72 million. During the same period in the previous year, the business posted $0.16 earnings per share. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. Analysts expect that Repligen Corporation will post $0.58 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/08/08/repligen-corporation-rgen-shares-bought-by-louisiana-state-employees-retirement-system.html.

A number of analysts recently weighed in on RGEN shares. First Analysis reaffirmed an “equal weight” rating and issued a $40.00 price objective on shares of Repligen Corporation in a report on Friday, April 21st. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Thursday, May 11th. BidaskClub cut shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Janney Montgomery Scott increased their price objective on shares of Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.20.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply